Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149095 | 0.88 | PTGER1 (0.54) | PTGER1CYP2C9MEN1KMT2ASLC6A3 | |
| SCHEMBL4150152 | 0.87 | PTGER1 (0.51) | PTGER1CYP2C9MEN1KMT2ASLC6A3 | |
| SCHEMBL4170731 | 0.87 | PTGER1 (0.72) | PTGER1CYP2C9 | |
| SCHEMBL4147587 | 0.85 | PTGER1 (0.84) | PTGER1CYP2C9 | |
| SCHEMBL4150739 | 0.84 | PTGER1 (0.68) | PTGER1CYP2C9 | |
| SCHEMBL4154388 | 0.80 | PTGER1 (0.73) | PTGER1CYP2C9MAPT | |
| SCHEMBL4154382 | 0.79 | PTGER1 (0.57) | PTGER1CYP2C9 | |
| SCHEMBL4159511 | 0.78 | PTGER1 (0.54) | PTGER1CYP2C9MEN1KMT2ANPC1 | |
| SCHEMBL4168890 | 0.78 | PTGER1 (0.90) | PTGER1CYP2C9 | |
| SCHEMBL4159750 | 0.77 | PTGER1 (0.85) | PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885MEN1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.